Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading

Jones Trading upgraded shares of Theravance Biopharma (NASDAQ:TBPH - Free Report) to a strong-buy rating in a research note released on Tuesday, MarketBeat reports. They currently have $24.00 price target on the biopharmaceutical company's stock.

TBPH has been the topic of a number of other reports. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.50.

Theravance Biopharma Price Performance

Shares of TBPH traded up $0.01 during mid-day trading on Tuesday, reaching $10.63. The company's stock had a trading volume of 193,858 shares, compared to its average volume of 274,417. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.82. The stock has a market cap of $531.50 million, a PE ratio of -9.01 and a beta of -0.09. The company's 50 day moving average is $9.74 and its 200 day moving average is $9.47.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. As a group, sell-side analysts anticipate that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after acquiring an additional 2,060 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth about $103,000. Magnetar Financial LLC grew its holdings in shares of Theravance Biopharma by 125.8% during the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 15,328 shares during the period. American Century Companies Inc. increased its position in Theravance Biopharma by 11.9% during the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 8,289 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Theravance Biopharma in the fourth quarter valued at approximately $69,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.